Coagulation potentials of plasma‐derived factors VIIa and X mixture (Byclot<sup>®</sup>) evaluated by global coagulation assay in patients with acquired haemophilia A-Reference-Cited by-同舟云学术

Coagulation potentials of plasma‐derived factors VIIa and X mixture (Byclot^®) evaluated by global coagulation assay in patients with acquired haemophilia A

Published:2023-11-29 Issue:1 Volume:30 Page:249-252
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Takeyama Masahiro¹²^ORCID,Furukawa Shoko¹^ORCID,Ogiwara Kenichi¹,Tamura Shinobu³,Ohno Hitoshi⁴,Higasa Satoshi⁵,Shimonishi Naruto¹⁶^ORCID,Nakajima Yuto¹⁷^ORCID,Onishi Tomoko¹⁸^ORCID,Nogami Keiji¹^ORCID

Affiliation:

1. Department of Pediatrics Nara Medical University Kashihara Nara Japan

2. Divison of Hemophilia National Hospital Organization, Osaka National Hospital Osaka Osaka Japan

3. Department of Hematology Wakayama Medical University Wakayama, Wakayama Japan

4. Department of Hematology Tenri Hospital Tenri Nara Japan

5. Department of Respiratory Medicine and Hematology Hyogo College of Medicine Nishinomiya Hyogo Japan

6. The Course of Thrombosis and Hemostasis Molecular Pathology Nara Medical University Kashihara Nara Japan

7. Advanced Medical Science of Thrombosis and Hemostasis Nara Medical University Kashihara Nara Japan

8. Center for Postgraduate Training Nara Medical University Hospital Kashihara Nara Japan

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14902

Reference10 articles.

1. A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics

2. A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors

3. Perioperative safety and haematostatic efficacy of a new bypassing agent pd-FVIIa/FX (Byclot) in haemophilia patients with high-responding type inhibitors

4. Plasma-derived factors VIIa and X mixtures (Byclot®) significantly improve impairment of coagulant potential ex vivo in plasmas from acquired hemophilia A patients

5. Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetics and Epigenetics in Acquired Hemophilia A: From Bench to Bedside;Current Issues in Molecular Biology;2024-05-23

2. Acquired Hemophilia A Diagnosed Based on Gross Hematuria: A Case Report and Literature Review;Case Reports in Urology;2024-01